# LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

> **NCT06198413** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Innostellar Biotherapeutics Co.,Ltd** · enrollment: 12 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **GENETIC:** LX102 subretinal injection

## Key facts

- **NCT ID:** NCT06198413
- **Lead sponsor:** Innostellar Biotherapeutics Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-27
- **Primary completion:** 2024-12-26
- **Final completion:** 2029-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06198413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06198413, "LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06198413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*